TW410160B - Adolescent dietary composition - Google Patents
Adolescent dietary composition Download PDFInfo
- Publication number
- TW410160B TW410160B TW084110289A TW84110289A TW410160B TW 410160 B TW410160 B TW 410160B TW 084110289 A TW084110289 A TW 084110289A TW 84110289 A TW84110289 A TW 84110289A TW 410160 B TW410160 B TW 410160B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- composition
- vitamin
- cns
- ministry
- Prior art date
Links
- 235000007882 dietary composition Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 95
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 235000016709 nutrition Nutrition 0.000 claims abstract description 12
- 230000035764 nutrition Effects 0.000 claims abstract description 8
- 229940024606 amino acid Drugs 0.000 claims description 32
- 235000001014 amino acid Nutrition 0.000 claims description 31
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- -1 hydrogen ester Chemical class 0.000 claims description 21
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 11
- 239000004395 L-leucine Substances 0.000 claims description 11
- 235000019454 L-leucine Nutrition 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 11
- 229960003136 leucine Drugs 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 10
- 229960003067 cystine Drugs 0.000 claims description 10
- 229960004441 tyrosine Drugs 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- 239000004158 L-cystine Substances 0.000 claims description 9
- 235000019393 L-cystine Nutrition 0.000 claims description 9
- 229930182821 L-proline Natural products 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 230000002079 cooperative effect Effects 0.000 claims description 9
- 229960004452 methionine Drugs 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 229960002429 proline Drugs 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 9
- 239000003549 soybean oil Substances 0.000 claims description 9
- 229960002898 threonine Drugs 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 8
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 8
- 229960005261 aspartic acid Drugs 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 229930182844 L-isoleucine Natural products 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 239000004368 Modified starch Substances 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 229960003767 alanine Drugs 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 229960001153 serine Drugs 0.000 claims description 6
- 235000015170 shellfish Nutrition 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229960004799 tryptophan Drugs 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 4
- 201000010538 Lactose Intolerance Diseases 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- 229960002079 calcium pantothenate Drugs 0.000 claims description 4
- IWIRHXNCFWGFJE-UHFFFAOYSA-L calcium;2,3-dihydroxypropyl phosphate Chemical compound [Ca+2].OCC(O)COP([O-])([O-])=O IWIRHXNCFWGFJE-UHFFFAOYSA-L 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001755 magnesium gluconate Substances 0.000 claims description 4
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 4
- 229960003035 magnesium gluconate Drugs 0.000 claims description 4
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 4
- 229920000223 polyglycerol Polymers 0.000 claims description 4
- 229940108325 retinyl palmitate Drugs 0.000 claims description 4
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 4
- 239000011769 retinyl palmitate Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000011684 sodium molybdate Substances 0.000 claims description 4
- 235000015393 sodium molybdate Nutrition 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- 206010025476 Malabsorption Diseases 0.000 claims description 3
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 235000020247 cow milk Nutrition 0.000 claims description 3
- 208000001848 dysentery Diseases 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229940050410 gluconate Drugs 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- 229940099596 manganese sulfate Drugs 0.000 claims description 2
- 239000011702 manganese sulphate Substances 0.000 claims description 2
- 235000007079 manganese sulphate Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- WREGJJDAANOZGJ-KDDYFZQKSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N WREGJJDAANOZGJ-KDDYFZQKSA-N 0.000 claims 1
- IVWJIJRWSKPNLJ-LELNYTAUSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@@H](O)[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 IVWJIJRWSKPNLJ-LELNYTAUSA-N 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008081 Intestinal Fistula Diseases 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- OZBJWQQAAQSQPL-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N OZBJWQQAAQSQPL-WCCKRBBISA-N 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- VPFISZQQQJYWPB-BTVCFUMJSA-N copper;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound [Cu].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VPFISZQQQJYWPB-BTVCFUMJSA-N 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 claims 1
- 239000004245 inosinic acid Substances 0.000 claims 1
- 229940028843 inosinic acid Drugs 0.000 claims 1
- 230000026045 iodination Effects 0.000 claims 1
- 238000006192 iodination reaction Methods 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 claims 1
- NVIFVTYDZMXWGX-UHFFFAOYSA-N sodium metaborate Chemical compound [Na+].[O-]B=O NVIFVTYDZMXWGX-UHFFFAOYSA-N 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- KORBDTTXVKJAGP-UHFFFAOYSA-H tricalcium propane-1,2,3-triol diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OCC(O)CO KORBDTTXVKJAGP-UHFFFAOYSA-H 0.000 claims 1
- 125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 abstract description 14
- 150000001720 carbohydrates Chemical class 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 229930182816 L-glutamine Natural products 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- 235000013350 formula milk Nutrition 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940045999 vitamin b 12 Drugs 0.000 description 4
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 4
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 3
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229960000645 histamine hydrochloride Drugs 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940108925 copper gluconate Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OXIKLRTYAYRAOE-CMDGGOBGSA-N (e)-3-(1-benzyl-3-pyridin-3-ylpyrazol-4-yl)prop-2-enoic acid Chemical compound N1=C(C=2C=NC=CC=2)C(/C=C/C(=O)O)=CN1CC1=CC=CC=C1 OXIKLRTYAYRAOE-CMDGGOBGSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- NAVWVHRQSDHCHD-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;potassium Chemical compound [K].OC(=O)CC(O)(C(O)=O)CC(O)=O NAVWVHRQSDHCHD-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- MXQXWJVQZHHBJV-UHFFFAOYSA-N 7h-purine-2-carboxylic acid Chemical compound OC(=O)C1=NC=C2N=CNC2=N1 MXQXWJVQZHHBJV-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- UQONAEXHTGDOIH-AWEZNQCLSA-N O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 Chemical compound O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 UQONAEXHTGDOIH-AWEZNQCLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZZQAGTCHSYAZCP-UFLZEWODSA-N [Cu].OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 Chemical compound [Cu].OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 ZZQAGTCHSYAZCP-UFLZEWODSA-N 0.000 description 1
- IICIEHGWOCSVHT-UHFFFAOYSA-N [Na].[Na].[Ar] Chemical compound [Na].[Na].[Ar] IICIEHGWOCSVHT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- TXXVQZSTAVIHFD-DKWTVANSSA-M potassium;(2s)-2-aminobutanedioate;hydron Chemical compound [K+].[O-]C(=O)[C@@H](N)CC(O)=O TXXVQZSTAVIHFD-DKWTVANSSA-M 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- ZNVNXKULFRSTGD-UHFFFAOYSA-N sulfuric acid pentahydrate Chemical compound S(=O)(=O)(O)O.O.O.O.O.O.S(=O)(=O)(O)O ZNVNXKULFRSTGD-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pediatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
經濟部中央標準局員工消費合作杜印製 ___β〇 :77_ 五、發明説明(1 ) 本發明係有關一種食療組合物,係用於提供人類的青 少年營養,尤其在1至18歲,供刺激生長或供疾病或症狀, 諸如發炎性腸疾,難醫治的痢疾,乳糖不適應症,短暫膀 疾症候群,膀胱的織維變性,牛乳蛋白質腸疾或敏感性, 手術前或手術後,後天性免疫不全症候群,吸收不良症, 胃腸炎,胃縢4管和胰臟異常者。 在青少年提供適當的營養對生長與發育極為重要。對 於青少年會遭遇到某些症狀或疾病而言,營養更是特別地 重要,以及不能由口服消化食物而必須經由腾管餵入者。 醫師必須使用嬰兒配方或改良現存的成人腸食配方,以符 合他們青少年期病人的需求*他們必需添加脂肪和糖類, 以增加熱卡,降低蛋白質含量,或減少用水供製俤粉末或 濃縮產品。這些改良不能提供良好均衡的配方,如鈉及雉
I 生素及礦物質不是很適當的。一些醫師曾經添加鐵,維生 素和鈣,但是再一次無法達到一種適當地均衡的配方。因 此一種強烈的需求存在於改良的腸食或口服配方設計以提 供青少年營養的需求。 腸食食物組合物含有必需的胺基酸,礦物質和糖類並 被揭示於美國專利第3,697,287號。美國專利第4,368,204 號則揭示供小兒使用的基本營養組合物,其具有一種特殊 的胺基酸分配。然而,前案之組合物提供給人類青少年的 營養則不甚理想。這些組合物為典型地在滲透壓為太高及 成長所需要必須的胺基酸及其他組成份的數董為相當地 低。 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ^ΐτ# (請先閱讀背面之注意事項再填寫本頁) «0160 «0160 經濟部中央標準局負工消費合作社印製 A7 B7 五、發明説明(2 ) 本發明克服前案组合物之缺陷,並藉由提供一種改良 的營養性組合物以提供給青少年,其具有一種最理想的胺 基酸含量。 本發明组合物包括: a) 一種糖類組成份’其包括所述组合物全部熱卡含量由 50至 65% ; b) 一種脂質组成份,其包括所述组合物全部熱卡含量由 20至35% ;以及 c) 一種胺基酸组成份’其包括所述組合物全部熱卡含量 由10至20% ;以及其包括2.3至2.8% L-组織胺酸,6.1 至7.4% L-異白胺酸,8_5至10.2% L-白胺酸,7.0至8.4% L-纊胺酸,6.6至8.0% L-賴胺酸,3.1至3.8% L-甲硫胺 酸,5.5至6.6% L-苯丙胺酸,4.8至S_8% L-蘇胺酸, 1.7至2.1% L-色胺酸,5·7至6.9% L-丙胺酸,6.2至7.5 % L-精胺酸,5.9至7_1%L-天冬胺酸,2·3至2,8%L-胱胺 酸,12.9至15.5% L-穀胺鎗胺,3.8至4.6% L-榖胺酸, 3.2至3.9%甘胺酸,5.0至6.0% L-脯胺酸,5.4至6.5% L-絲胺酸和4.0至4.8% L-酪胺酸,所有均基於所述胺 基酸組成份的全部重量計算。 本發明组合物的糖類組成份包括組合物全部熱卡含量 之50至65%,更佳為全部熱卡含量之60至65%;最佳為全 部熱卡含董之63%»任何糖類傳統使用於營養組合物均可 用'於本發明組合物,但較佳的糖類組成份主要包括麥芽糖 糊精(maltodextrin)。改質澱粉或其混合物。糖類組成份 5 本紙張尺度適用中國國家標準(CNS ) A4規格(:210X 297公釐) . ^—參..— (請先聞讀背面之注意事項再填寫本I) 訂- A7 41016° _B7 五、發明説明(3 ) — ^nn ^^^1 II - - ------ I1*^^^^1 0¾-- (請先閱讀背面之注意事項再填寫本頁) 提供糖類任意地吸收,經由青少年的胃-勝消化道,尤其是 對這些吸收作用異常者亦然*糖類組成份更佳主要包括約 72至99重量%麥芽糖糊精,以及約1至28重量%改質澱粉。 糖類组成份較佳為不含乳糖C其可能困擾著具有乳糖不適 應症的青少年)以及較佳是不含蔗糖或果糖。 本發明組合物之脂質組成份包括组合物全部熱卡含量 之20至35%,更佳為20至30%,最佳為約25% '充足的脂 質攝取對於能量的來源,必須的脂肪酸,和脂溶性維生素 之載«甚為重要。適當的脂質使用於本發明,包括任何傳 統的飽和及不飽和脂肪酸,甘油酯和其他營養上可接受並 為此技藝所知悉的脂肪來源,諸如動物油脂,魚類油脂, 蔬菜油和合成脂質。較佳的脂質組成份主要地包括大豆 油,中鍵甘油三酸酯或其混合物。更佳為,脂質組成含有
I 經濟部中央標準局貝工消費合作社印製 約30重量%大豆油及約70重董%中鏈甘油三酸酯,基於所 述脂質組成份全部重量計算。中鏈甘油三酸酯曾被顯示在 臨床的症狀具有良好的利用,由於標準長鏈食用的脂肪吸 收不良。再者,中鏈甘油三酸酯含有脂肪酸鏈包括6至10 直線型碳單元*這些甘油三酸酯不需要以膽汁乳化,所以 比長鏈脂肪和脂肪酸更迅速和更容易水解以進入門靜脈系 統直接地吸收》大豆油如一種源自質優的亞油酸及亞麻酸 為較佳的。本發明組合物較佳包括在全部能源含量約4·3% 為亞油酸,以及約0.6%為亞麻酸,得到全量約4.9%的必需 脂肪酸。 脂質組成份較佳添入或包含在本發明組合物内,其係 6 本紙張尺度通用中國固家標準(CNS ) Λ4規格(210Χ 297公釐) 經濟部中央標準局員工消費合作社印製 410160 A7 B7 五、發明説明(4 ) 以糖類膠囊化的乾燥顆粒形式為之。膠囊化脂質之製價, 可由將胳質添加一種糖類漿狀水液,將其均質化,並嗔霧 乾燥成為乾燥顆粒的形式。膠囊化脂質為本發明组合物提 供改良穩定的乳化液。 本發明組合物之胺基酸組成份包括由组合物之全部熱 卡含量之10至20%,更佳為10至15%,最佳為約i2〇/b,更 佳的胺基酸組成份包括2.4至2.6% L-組織胺酸,6.6至6.8% L-異白胺酸,9.2至9.5% L-白胺酸,7·6至7.8% L-蝴胺酸, 7.1至7.4%賴胺酸,3.3至3.5% L-甲硫胺酸,6.0至6.2% L-笨丙胺酸,5_2至5.4% L-蘇胺酸,1.8至2.0% L-色胺酸, 6.2 至 6.4%L-丙胺酸,6.7 至 6.9%L-精胺酸,6.4 至 6.6%L-天冬胺酸,2.4至2.6% L-胱胺酸,14.0至14.5% L-榖胺醯 胺,4.1至4.3% L-穀胺酸,3.4至3.6%甘胺酸,5.4至4.6% L-脯胺酸,5.8至6.1% L-絲胺酸以及4.3至4. S%L-酪胺酸, 所有均基於所述胺基酸组成份的全部重量計算。最佳的胺 基酸组成份包括約2.5% L-组織胺酸,6.7% L-異白胺酸, 9.4% L-白胺酸,7.7% L-纈胺酸,7.3%頻胺酸,3.4% L·-甲硫胺酸,6.1%L-笨丙胺酸,5·3%L-蘇胺酸,1.9%L-色胺酸,6.3% L-丙胺酸,6.8% L-精胺酸,6.5%L-天冬胺 酸’ 2.5%L-胱胺酸,14.2%L-穀胺釀胺,4.2%L-毅胺酸, 3.5%胺酸,5.5% L-脯胺酸,5.9% L-綵胺酸以及4.4% L-酪胺酸,所有均基於所述胺基酸组成份的全部重量計算。 本發明组合物較佳含有100%自由胺基酸,特別設計一 種均街的胺基酸提供給青少年。胺基酸之均衡相對於完整 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210x297公釐} - - l^—ί In ln^i ^^^1 I- n^i 1 (請先閲讀背面之注意事項再填寫本頁) 訂 *10160 A7 --- B7 - — 五、發明説明(5 ) (請先閱讀背面之注意事項再填寫本頁) 的蛋白質使用於其他配方為一種似變應性的(hyp〇_aH ergenic)。自由胺基酸在青少年對完整蛋白質敏感者之膳 食管理以及飯食給具有嚴重和持續性痢疾的青少年而言, 具有一種奇特的益處。此组合物之胺基酸分配(pr〇file)符 合或超出國家科學院-國家研究委貝會所制訂高品質蛋白 質之標準。較佳的非蛋白質熱卡對氮比率為200:1,以及 較佳全部熱卡對氮比率為227:1,此將符合青少年期患者 的需求。通常,在刺激期間蛋白質需求量增加,由於損耗 增加以及代謝(anabolism)較大的需求和组織修復。研究曾 經顯示腸的加強滋養係使用足夠量的蛋白質,可以加速内 臟的蛋白質合成’並促進正值氮氣平衡以及寄主防禦因 责。然而,超過標準的蛋白質為相反地,因為其結果為賢 臟過度負荷的增加。 胺基酸組成份較佳含有9.S至11.5重量%芳香族胺基 酸(諸如,苯丙胺酸和酪胺酸)和5.4至6.5重量%含硫胺基酸 (諸如,甲硫胺酸和胱胺酸),基於胺基酸組成份之全部重 量計算。這些被認為在青少年成長之中為最重要的胺基 酸。 經濟部中央棉隼局負工消費合作社印製 本發明组合物較佳含有L-肉鹼及牛磺酸。足夠量的L-肉鹼為脂質代謝所必需。组合物以全部组合物乾重計算較 佳含有由約〇·〇1至約0.02重量%之L-肉鹼。牛磺酸在正常 的視網膜發展以及在膽鹽類的合成極為重要。牛磺酸亦有 助於改善脂肪的吸收,成長及體重增加。較佳的組合物以 全部组合物乾重計算含有約0.04至0.05重量%的牛磺酸。 8 本紙張尺度逋用中國國家標準(CNS ) Λ4規格(2!〇χ297公釐) 410160 A7 ____B7 五、發明説明(6 ) 本發明組合物可為一種固想粉末形式。此種粉末其次 地溶解於或分散於汁液’水或其他水液為主,非蛋白質介 質。此固艘粉末形式較佳具有一種熱卡含量為約4至5卡/ 每克组合物。組合物亦可為立即可使用水溶液形式,其較 佳具有一種熱卡含量為約0.8卡/每毫升。本發明水液組合 物較佳具有一種滲透壓為約300至400 mOsm/每公斤水, 更佳為約350至370 mOsm/公斤;最佳為約360 mOsm/公 斤。同樣地,0.22克的乾燥粉末组成物在1克水中,具有 一種滲透壓為300至400 mOsm* 較佳的本發明组合物具有下述的配方,係基於組合物 的全部乾燥重量計算: 組成份 重量% 麥芽糖糊精 42.5960 至 52.0618 改質澱粉 16.3556 至 19.9901 中鏈甘油三酸酯 7.5770 至 9.2608 大豆油 3.2834 至 4.0130 甘油磷酸鈣 2.8007 至 3.4231 葡萄糖酸鎂 1.8886 至 2.3083 L-榖胺醯胺 1.4374 至 1.7568 L-賴胺酸乙酸鹽 1.0375 至 1.2681 L-白胺酸 0.9471 至 1.1576 L-精胺酸乙酸鹽 0.9289 至 1.1354 氯化鉀 0.7879 至 0.9630 L-纈胺酸 0.7800 至 0.9533 經漓部中央梯準局員工消費合作社印製 -n· n 1 .—r I _----^ - - n n _ _ I 1-*a (請先閱讀背面之注意事項再填寫本頁) 9 本紙張尺度適用中國國家標準(CMS ) A4規格(2丨0 X 297公釐) Α7 Β7 --- .^ϋ —^ϋJ_-_ n ^^1 - I - - - j I —i VeJ (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 五、發明説明(7 ) 檸檬酸 L-異白胺酸 L-天冬胺酸 L-丙胺酸 L-苯丙胺酸 L-絲胺酸 聚甘油睡 L-脯胺酸 L·蘇胺酸 L-酪胺酸 L-縠胺酸 檸樣酸鉀 甘胺酸
I L-组織胺酸盥酸鹽 L-甲硫胺酸 檸樣酸鈉 L-胱胺酸 膽鹼二酒石酸氩酯 L-色胺酸 雄酸氩二鈉 山梨酸鉀 抗壞血酸 α -生育酹乙酸酯 /8 ·胡蘿«素 0.7428 至 0.9079 0.6797 至 0.8307 0.6574 至 0.8035 0.6351 至 0.7763 0.6128 至 0.7490 0.6017 至 0.7354 0.5669 至 0.6929 0.5571 至 0.6809 0.5348 至 0.6537 0.4457 至 0.5448 0.4234 至 0.5175 0.3580 至 0.4376 0.3566 至 0.4358 0.3463 至 0.4233 0.3454 至 0.4222 0.2764 至 0.3378 0.2563 至 0.3132 0.2386 至 0.2916 0.1894 至 0.2315 0.1818 至 0.2223 0.1746 至 0.2134 0.0938 至 0.1146 0.0836 至 0.1021 0.0487 至 0.0595 10 本紙張尺度適用中國國家標準{ CNS )八4規格(210X297公嫠) A7 B7 經濟部中央標隼局I工消費合作社印掣 五、發明説明(8 ) 牛磺酸 M-肌醇 硫酸鋅 硫酸亞鐵 菸鹼醢胺 L-肉鹼 生物素 葡萄糖酸銅 泛酸鈣 維生素A棕櫊酸酯 硫酸鉉 維生素D 3 維生素K】 維生素B 12 碘化鉀 吼哆酵鹽酸鹽 紫酸 核黃素 硫胺素鹽酸鹽 鉻酸乙酯單水合物 鉬酸鈉 亞场酸鈉無水物 全量 0.0415 至 0.0507 0.0338 至 0.0413 0.0178 至 0.0218 0.0165 至 0.0201 0.0133 至 0.0162 0.0130 至 0.0158 0.0065 至 0.0079 0.0047 至 0.0057 0.0037 至 0.0046 0.0037 至 0.0045 0.0033 至 0.0041 0.0032 至 0.0040 0.0025 至 0.0031 0.0020 至 0.0025 0.0018 至 0.0021 0.0016 至 0.0020 0.0013 至 0.0016 0.0012 至 0.0015 0.0010 至 0.0013 0.00010 至 0.00011 0.00010 至 0.00011 0.000040 至 0.000044 100 更佳的組合物包含,係基於组合物之全部乾燥重量為 _11 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印掣 A7 __^10160_ 五、發明説明(9 ) 計算如下: 組成份 重量% 麥芽糖糊精 42.3289 改質澱粉 18.1728 中鏈甘油三酸酯 8.4189 大豆油 3.6482 甘油磷酸鈣 3.1119 葡萄糖酸鎂 2.0985 L-穀胺醢胺 1.5971 l-賴胺酸乙酸a 1.1528 L-白胺酸 1.0524 L-精胺酸乙酸鹽 1.0321 氣化鉀 0.8755 L-纊胺酸 0.8667 檸樣酸 0.8254 L-異白胺酸 0.7552 L-天冬胺酸 0.7305 L-丙胺酸 0.7057 L-苯丙胺酸 0.6809 L-綵胺酸 0.6686 聚甘油酯 0.6299 L-脯胺酸 0.6190 L-蘇胺酸 0.5943 L-酪胺酸 0.4952 -------;---裝— (請先閱讀背面之注意事項再填寫本頁) 訂 12 本紙張尺度適用中國國家標準(CNS ) Λ4規格(2]〇X 297公釐) 410160 A7 B7 五、發明説明(10 ) 經濟部中央標準局貝工消費合作社印製 L-穀胺酸 0.4705 檸檬酸鉀 0.3978 甘胺酸 0.3962 L-組織胺酸鹽酸鹽 0_3848 L-甲硫胺酸 0.3838 檸樣酸鈉 0.3071 L-胱胺酸 0.2848 赡鹼二酒石酸氩酯0.2651 L-色胺酸 0.2105 磷酸氫二鈉 0.2021 山梨酸鉀 0.1940 抗壞血酸 0.1042 α-生育酚乙酸酯 0.0929 /5-胡蘿蔔素 0.0541 牛磺酸 0.0461 Μ-肌酵 0.0375 硫酸鋅 0.0198 硫酸亞鐵 0.0183 菸鹼醢胺 0.0147 L-肉鹼 0.0144 生物素 0.0072 葡萄糖酸銅 0.0052 泛酸鈣 0.0042 維生素Α棕櫊酸酯0.0041 13 本紙張尺度適用辛國國家標準(CNS ) Λ4規格(210X297公漦) i —^1 ^^1 —r I- - ---- —I - - - «^n ^1« 、-* (請先閱讀背面之注意事項再填寫本頁) Α7 Β7 五、發明説明(11 ) 硫酸鏟 0.0037 維生素D 3 0.0036 維生素K i 0.0028 維生素B 12 0.0023 碘化鉀 0.0019 吡哆醇鹽瞍鹽 0.0018 紫酸 0.0014 核黃素 0.0013 硫胺素躉酸鹽 0.0012 鉻酸乙酯單水合物 0.0001 鉬酸鈉 0.0001 亞硒酸納無水物 0.00004 全董 100 ^1· ^^^1 n^i HI 11> In I ^^^1 1^1 (請先閲讀背面之注意事項1填寫本i} ,ιτ 經濟部中央標準扃員工消费合作社印製 本發明之經腸營養性组合物之給予,可經由一種鼻 胃’鼻勝,食管造口術,胃造口術,或空腸透口術給養管。 因為其均質性和低粘度,水孔給養管(16徑計導管或#5 French管)可依過去曾做過的病患耐受性做最有效的運 用。食物可在室溫下給予,由連續的滴注技術,或使用一 種適當的注入泵。在0.8卡/每毫升稀釋液,組合物可供應 大部份的每天流醴需求^增添的流《I可以給予,當需要維 持水合作用及足夠的尿液排出》 組合物亦可口服給予,諸如一種調咮飲料充作冰果。 本發明组合物可用於給予完整的營養或營養補充,較佳為 14 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公釐) A7 B7 五、發明説明(12 ) 1至18歲的青少年,更佳為玉至忉歲,最佳為1至6歲。組合 物較佳的給予量為至少提供8〇〇卡/天。組合物尤其可用於 給予某些疾病症狀的青少年,諸如發炎性腸疾,難醫治的 病疾,乳糖不適應症,短暫腸疾症候群,膀胱的織維變性, 牛乳蛋白質腸疾或敏感性,手術前或手術後,外傷性症狀, 後天性免疫不全症候群,吸收不良症,胃腸炎,胃腸勡管 和胰臟異常者。 下列實施例用來幫助論證本發明β這些貧施例為列舉 性不是作為限制之用》 實施例 一種食療組合物(樣品#8773)具有一種胺基酸分配在 本發明範疇之内,與一種食療组合物含有酪蛋白,當標準
I 的蛋白質來涿比較》這些組合物具有下列配方: -------;—裝— (請先聞讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局貝工消費合作社印製 fc成份 用董f重詈%) 樣品#8733 酪蛋白组 酪蛋白 - 11.14 胺基酸混合物* 11.70 - 拂子油 8.00 7.96 維生素混合物 1.00 1.00 鹽類混合物 5.00 4.81 非營養性纖維 1.00 1.00 玉米激粉 34.15 34.15 蔗糖 34.15 35.59 15 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公嫠) r 經濟部中央標準局員工消費合作杜印製 A7 B7 五、發明説明(13 ) 水 S_00 4.35 *胺基酸混合物包括: 组成份 重量% L-穀胺醸胺 12.2 L-白胺酸 8.0 L-精胺酸乙酸鹽 7.9 L-賴胺酸乙酸鹽 8.8 L·-異白胺酸 5.8 L-纈胺酸 6.6 L-苯丙胺酸 5.2 L-甲硫胺酸 2.9 L-蘇胺酸 4.5 L-酪胺酸 3.8 L-組織胺酸鹽酸鹽 2.9 L-天冬胺酸 5.6 L-脯胺酸 4.7 L-色胺酸 1.6 L-絲胺酸 5.1 L-丙胺酸 5.4 甘胺酸 3.0 L-毅胺酸 3.6 L-胱胺酸 2.2 此组合物經比較其蛋白質利用率(PER),其係以實驗 16 --------^---裝-- (请先鬩讀背面之注意事項再填寫本頁) 訂 本紙張·尺度適用中國國家標準(CNS ) Λ4規格(210 X 297公釐〉 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(14 ) 室的老鼠測定蛋白質品質。PER之測定,將經由蛋白質的 吸收使動物的髏重增加來區分。兩組各10隻老鼠分別地餵 食樣品#8773及酪蛋白組成物經28天。每7天老鼠之體重秤 重之並記錄它們的食物消耗量。在28天終了,計算兩組之 全部體重的增加及蛋白質的消耗量。這些數值用來計算 PER。 酪蛋白组成物之結果示於表1,而本發明樣品#8733 示於表2。 表1 (酪蛋白組成物) tt重-克 遇數 I I"f (請先鬩讀背面之注意事項再填寫本頁) 17 動物編號 0 1 2 3 4 獲得體重 1 65 ,82 106 129 162 97 2 64 84 106 129 156 92 3 61 81 104 129 164 103 4 62 78 99 119 155 93 5 65 89 119 144 183 118 6 61 80 111 139 167 106 7 62 80 102 129 158 96 8 63 87 113 135 173 110 9 66 87 115 142 179 113 10 64 91 124 152 189 125 平均值 63 84 110 135 169 105 標準偏差 1.77 4.38 7.92 9.63 11.90 11.16 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 經濟部中央標準局員工消費合作社印製 A7 ---410160-— 五、發明説明(15 ) 飼料消耗-克 遇數 動物編號 1 2 3 4 全量 蛋白質 PER* 1 69 97 96 98 360 36.0 2.69 2 75 88 96 95 354 35,4 2.60 3 69 86 89 103 347 34.7 2.97 4 72 81 87 114 354 35.4 2.63 5 81 101 109 121 412 41.2 2.86 6 73 96 109 106 384 38.4 2.76 7 74 84 101 112 371 37.1 2.59 8 80 89 94 116 379 37.9 2.90 9 78 98 102 120 398 39.8 2.84 10 85 107 113 129 434 43.4 2.88 平均值 76 93 100 111 379 37,9 2.77 標準偏差 5.30 8.33 8.77 10.8128.28 2.83 0.138 *PER=蛋白質利用率 (請先閱讀背面之注意事項再填寫本頁) 裝· 丁 -5 本紙張尺度適用中國國家標隼(CNS ) A4規格(2 i Ο X 297公釐) A7 __II016 Q_ 五、發明説明U ) 表2 樣品#8773 «重-克 遇數 經濟部中央標準局員工消費合作社印聚 動物編號 0 1 2 3 4 獲得體重 1 64 105 163 216 272 208 2 65 93 138 182 225 160 3 63 91 133 179 231 168 4 62 94 150 198 250 188 5 60 86 128 164 202 142 6 62 86 130 175. 218 156 7 61 87 129 177 222 161 8 62 86 129 172 211 149 9 60 89 139 190 241 181 10 61 85 125 171 214 153 平均值 62 90 136 182 229 167 標準偏差 1.63 6.09 11.8 15.28 20.82 20.19 飼料消耗-克 遇數 動物編號 1 2 3 4 全量 蛋白質PER 1 94 133 148 153 528 52.8 3.94 2 82 120 138 141 481 48.1 3.33 3 74 113 136 145 468 46.8 3.59 4 82 133 139 146 500 50.0 3.76 5 70 110 119 119 418 41.8 3.40 6 77 114 134 136 461 46.1 3.38 7 80 107 130 132 449 44.9 3.59 8 79 110 124 125 438 43.8 3.40 9 89 132 153 150 524 52.4 3.45 19 - I - I m n---- Jl^i uri i^i L-1^1 - — f^i ^lv Λ^*T (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0 X 297公釐) 410160 五、發明説明(rr ) 10 74 105 126 128 433 43.3 3.53 平均值 80 118 135 138 470 47.0 3.54 標準偏差 7.20 11.10 10.55 11.35 37.89 3.79 0-191 結果顧示本發明組合物具有胺基酸分配比傳统蛋_白 質,具有一種明顯地較大的蛋白質利用率(PER) » 實施例2 一種食療组合物在本發明範疇之内〔樣品A)經製儀舆 美圉專利第4,368,204號(樣品B)的一種食療组合物相比 較。 本發明樣品A具有下列组成: - - - . - -- i ....... —«^1 ^^^1 I. ^1 {請先閲請背面之注意事項#填寫本頁) 經濟部中央標準局貝工消费合作杜印聚 組成份 重董% 麥芽糖糊精 47.3289 改質it粉 18.1728 中鏈甘油三酸酯(MCT) 8.4189 大豆油 3.6482 甘油磷酸鈣 3.1119 萄萄糖酸鎂 2.0985 L-毅胺醢胺 1.5971 L-賴胺酸6酸鹽 1.1528 L-白胺酸 1.0524 L-精胺酸乙酸鹽 1.0321 氯化鉀 0.8755 L-纈胺酸 0.8667 20 訂 本紙張尺度適用中國國家標準(CNS ) Λ4規格(2丨0X297公釐) 經濟部中央標準局員工消費合作社印製 41〇16〇 at B7 五、發明説明(18 ) 檸樣酸 0.8254 L-異白胺酸 0.7552 L-天冬胺酸 1 0.7305 L-丙胺酸 0.7057 L-笨丙胺酸 0.6809 L-絲胺酸 0.6686 聚甘油酯 0.6299 L-脯胺酸 0.6190 L-蘇胺酸 0.5943 L-路胺酸 0.4952 L-穀胺酸 0.4705 檸樣酸鉀 0.3978 甘胺酸 0.3962 L-组織胺酸鹽酸鹽 0.3848 L-曱硫胺酸 0.3838 檸檬酸鈉 0.3071 L-胱胺酸 0.2848 膽鹼二酒石酸氫酯 0.2651 L-色胺酸 0.2105 磷酸氫二鈉 0.2021 山梨酸鉀 0.1940 抗壞血酸 0.1042 α -生育酚乙酸酯 0.0929 /3 -胡蘿葡素 0.0541 牛磺酸 0.0461 21 (請先閱讀背面之注意事項再填寫本頁) 丨參' 訂 本紙張尺度適用中國國家標隼(CNS ) Λ4規格(2丨Ο'〆297公1 ) 經濟部中央榡準局員工消費合作社印製 4l〇U〇五、發明説明(19 ) Μ-肌酵 硫酸鋅 硫酸亞鐵 菸鹼醯胺 L-肉鹼 生物素 葡萄糖酸銅 泛酸鈣 維生素Α棕櫊酸酯 硫酸錳 維生素D 3 維生素K, 維生素B 12 块化鉀 吡哆醇鹽酸鹽 葉酸核黃素 硫胺素盟酸鹽 鉻酸乙酯單水合物 鉬酸鈉 亞场酸納無水物 全量 樣品A之熱卡量為 A7 B7 0.0375 0.0198 0.0183 0.0147 0.0144 0.0072 0.0052 0.0042 0.0041 0.0037 0.0036 0.0028 0.0023 0.0019 0.0018 0.0014 0.00130.00120.0001 0.0001 0.00004 (請先閲讀背面之注意事項再填寫本頁) 100 基酸,25%脂質和63%糖類。 22 本紙乐尺度適用中國國家標準(CNS > Μ規格(2丨0X四7公釐) 410160 經濟部中央標準局員工消費合作杜印製 A7 B7 五、發明説明(2〇 ) 比較樣品B具有下列組成 : 组成份 重量% 糊精 82.40478 大豆油 3.14522 L-白胺酸 1.31575 L-脯胺酸 1.27906 L-丙胺睃 1.25809 L-賴胺酸單鹽酸魏 1.24367 L·絲胺酸 1.15718 L-穀胺酸 0.97895 L-精胺酸 0.90818 N -乙斑基-L-路胺酸 0.70505 L-纈胺酸 0.70374 L-異白胺酸 0.68015 L·蘇胺酸 0.65001 L-组織胺酸薆酸鹽 0.49799 L-胱胺酸鹽酸鹽單水合物 0.41019 L-苯丙胺酸 0.40626 二-L-天冬胺酸單鎂鹽 0.35842 L-天冬胺酸單鉀鹽 0.35842 甘胺酸 0.29749 硫酸鋅七水合物 0.28137 L-色胺酸 0.24375 23 (請先閲讀背面之注意事項再填寫本頁) 丨>衣. -0 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210 X 297公釐) 410160 五、發明説明(21 ) A7 B7 經濟部中央橾準局貝工消费合作社印袈 L-甲碑胺酸 0.20837 山梨酸鉀 0.15726 polysorbate 80 0.15412 葡萄糖敢亞鐵 0.05762 臆鹼二酒石酸氫酯 0.03916 抗壞i酸 0.03748 大豆卵磷脂 0.02202 維生素K 0.01922 硫酸銅五水合物 0.00180 生育酴乙酸酯 0.00722 菸鹼醯胺 0.00481 硫酸鏟五水合物 0.00285 泛酸鈣 0.00260 吼哆醇盥酸叟 0.00058 視黃酵乙酸酯 0.00049 硫胺素鹽酸鹽 0.00042 紫酸 0.00010 生物素 0.00009 核黃素磷酸鈉 0.00006 維生素D 2 0.00001 維生素Β 12 0.000001 全量 100 樣品B之熱卡量大致地為13%蛋白質,8%脂質,和79% 24 (請先閲讀背面之注意事項再填寫本頁) -訂 本紙張尺度適用中國®家標準(CNS ) Λ4说格(210X297公釐〉 經濟部中央標準局貝工消费合作社印製 410160五、發明説明T22 ) 糖類。 大致地60至80克樣品A及B,分別地溶解於溫水,以獲 得300毫升的溶液*這些溶液經製備及目測觀察以5個個體 評估其立即溶解性(instancy)及溶解度,使用5點指標,1 =不良,和5=優越。立即溶解性被定義為組合物成為溶 液所需時間,而溶解度被定義為組合物大部份成為溶液 後’不溶解的顆粒浮在表面。組合物亦以目測評估在溶液 表面之起泡性。這些評估的結果示於表3» ^__3^ 樣品A 樣品B (手均度)
It ml In In —rtn n I I I In In^e, (請先聞讀背面之注意事項再填寫本頁) 立即溶解性 3.2 1.4 溶解度 2.6 1.8 起泡性 無 4毫升 比較樣品B在混合後,顯示產品塊狀物浮在表面,而 本發明之樣品A之表面則無產品塊狀物浮在表面。比較樣 品B在靜置大約5分鐘以後’有一種白色的顆粒層在溶液底 面形成,而樣品A則無此種沈殿物。 實施例3 本發明组合物(樣品A)和比較组合物(樣品B)如實施例 ___25 本紙張尺度通用中國國家標準(CNS ) Λ4規格(210^297公楚) 表 4 41JD160 A7 B7 五、發明説明(23 ) 2所製備者,依照聯國糧農組織/世界衛生組織(FAO/WHO) 專家顧問對蛋白質品質評估(1989年)評估其蛋白質,其在 此引作參考文獻。以相對於蛋為100分作為參考蛋白質予 以評估组合物之分數》其結果的計分示於表4。 (請先閱讀背面之注意事項再填寫本頁) ,\=° 經濟部中央標準局貝工消費合作杜印製 由計分顯示,本發明組合物之必需胺基酸組成份與比 較先前技術叙成物相比較,具有較高的品質》S十分表示在 本發明组合物内限制的胺基酸為蛋參考蛋白質之94%,同 時,比較組合物之限制胺基酸僅為蛋參考蛋白質之57%。 26 樣品A 樣品B 胺基酸 參考蛋白質 (蛋〕 (毫以克) 胺基酸值 (毫克/克) 參考蛋白質 之% 胺基酸值 (毫克/克) 參考蛋白質 之% L-组織胺酸 22 23 105 24.3 110 L-異白胺酸 54 61 113 45 83 L-白胺酸 86 85 99 87 101 L-賴胺酸 70 66 94 65.8 94 L-甲硫胺酸 +L-胱胺酸 57 54 95 32.5 57 L-苯丙胺酸 +L-酪胺酸 93 95 102 64.8 70 L-蘇胺酸 47 48 102 43 91 L-色胺酸 17 17 100 16.2 95 L-纈胺酸 66 70 106 46.5 70 化學計分 100 94 57 本紙張尺度適用中國國家標準(CNS ) Μ規格(210 X 297公釐)
Claims (1)
- 經濟部中央標隼局員工消費合作社"聚 410160 韶 C8 D8 六、申請專利範圍 1·—種供人類青少年之口服或經腸道之食療組合物,其包 括: 组成份 重量% 麥芽糖糊精 42.5960 至 52.0618 改質澱粉 16.3556 至 19.9901 中鏈甘油三酸酯 7.5770 至 9.2608 大豆油 3.2834 至 4-0130 甘油磷酸鈣 2.8007 至 3.4231 葡萄糖酸鎂 1.8886 至 2.3083 L-毅胺醯胺 1.4374 至 1.7568 L-賴胺酸乙酸鹽 1.0375 至 1.2681 L-白胺酸 0.9471 至 1.1576 L-精胺酸乙酸鹽 0.9289 至 1.1354 氯化鉀 0.7879 至 0.9630 L-纗胺酸 0.7800 至 0.9533 檸檬酸 0.7428 至 0.9079 L-異白胺酸 0.6797 至 0.8307 L-天冬胺酸 0.6574 至 0.8035 L-丙胺酸 0.6351 至 0.7763 L-苯丙胺酸 0.6128 至 0.7490 L-絲胺酸 0.6017 至 0.7354 聚甘油酯 0.5669 至 0.6929 L-脯胺酸 0.5571 至 0.6809 L-蘇胺酸 0.5348 至 0.6537 27 I i I I— n s^. I ^ (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度逍用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央揉準局員工消費合作社印製 41Q160 it C8 D8 々、申請專利範圍 L-酪胺酸 0.4457 至 0.5448 L-毅胺酸 0.4234 至 0.5175 檸樣酸鉀 0.3580 至 0.4376 甘胺酸 0.3566 至 0.4358 L-組織胺酸鹽酸蕹 0.3463 至 0,4233 L-甲硫胺睃 0.3454 至 0.4222 檸檬酸鈉 0.2764 至 0.3378 L-胱胺酸 0.2563 至 0.3132 膽鹼二酒石睃氫酯 0.2386 至 0.2916 L-色胺酸 0.1894 至 0.2315 磷酸氫二鈉 0.1818 至 0.2223 山梨酸鉀 0.1746 至 0.2134 抗壞血酸 0.0938 至 0.1146 α-生育酚乙酸酯 0.0836 至 0.1021 β-_蘿SS素 0.0487 至 0.0595 牛磺酸 0.0415 至 0.0507 Μ -肌酵 0.0338 至 0.0413 硫酸鋅 0.0178 至 0.0218 硫酸亞鐵 0.0165 至 0.0201 菸鹼醯胺 0.0133 至 0.0162 L-肉鹼 0.0130 至 0.0158 生物素 0.0065 至 0.0079 葡萄糖酸銅 0.0047 至 0.0057 泛酸鈣 0.0037 至 0.0046 ---------^------、1T------Μ. (請先閱讀背面之注意事項再填寫本頁) 28 本紙張尺度適用中國國家標準(CNS) Α4规格(210Χ297公釐) 經濟部中央梯準局員工消費合作社印製 4ι〇1β〇 含§ _______D8 々、申請專利範圍~ 維生素Α棕櫊酸酯 0.0037 至 0.0045 硫酸錳 0.0033 至 0.0041 維生素d3 0.0032 至 0.0040 維生素Ki 0.0025 至 0.0031 維生素Bl2 0,0020 至 0.0025 碘化鉀 0.0018 至 0.0021 吨哆酵a酸鹽 0.0016 至 0.0020 葉酸 0.0013 至 0.0016 核黃素 0.0012 至 0.00X5 硫胺棄鹽酸鹽 0.0010 至 0.0013 鉻酸乙酯單水合物 0.00010 至 0.000Π 鉬酸鈉 0.00010 至 O.OOOH 亞场酸鈉無水物 0.000040 至 0.000044 全量 100 2. 如申請專利範圍第1項所述之組合物,其中所述之组合 物具有熱卡密度為約0.8卡/毫升以及滲透壓為300至 400 mOsm/公斤》 3. 如申請專利範圍第1項所述之组合物,其中所述之組合 物0.22克在1克水中,具有滲透壓為300至400 mOsm/ 公斤》 4. 如申請專利範圍第1項所述之组合物,其中所述之胺基 酸組成份包括由5.4至6.5重量%之含硫胺基酸。 5:如申請專利範团第1項所述之組合物,其中所述之胺基 酸纽成份包括由9.5至11·5重量%之芳香族胺基酸》 29 本紙張尺度適用中國國家標準(CNS ) Α4規格(2lOX297公嫠) ^------1Τ------^ (請先聞讀背面之注$項再填寫本頁) A8 BS C8 D8 經濟部中央標準局員工消費合作社印製 々、申請專利範圍 6.如申請專利範圍第1項所 組合物之全部乾燥重量 组成份 麥芽糖糊精 改質澱粉 中鏈甘油三酸酯 大豆油 甘油磷酸鈣 葡萄糖酸鎂 L-榖胺醯胺 L-頼胺酸乙酸鹽 L-白胺酸 L-精胺酸己酸鹽 I 氯化鉀 L-纈胺酸 檸樣酸 L-異白胺酸 L-天冬胺酸 L-丙胺酸 L-苯丙胺酸 L-絲胺酸 聚甘油81 L-脯胺酸 L-蘇胺酸 述之組合物,包括基於所述之 重量% 42.3289 18.1728 8.4189 3.6482 3.1119 2.0985 1.5971 1.1528 1.0524 1.0321 0.8755 0.8667 0.8254 0.7552 0.7305 0.7057 0.68090.6686 0.6299 0.6190 0.5943 30 ------『----^------1T------線 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標率局貝工消费合作社印製 410160 t、申請專利範圍 L-酪胺酸 L-穀胺酸 檸樣酸鉀 甘胺酸 L-組織胺酸鹽 L-甲硫胺酸 檸檬酸鈉 L-胱胺酸 膽鹼二酒石酸 L-色胺酸 磷酸氫二鈉 山梨酸鉀 抗壞i酸 I (Ϊ-生育酚乙酸 胡蘿葡素 牛磺酸 M-肌醇 硫酸鋅 硫酸亞鐵 菸鹼醢胺 L-肉鹼 生物素 葡萄糖酸銅 泛酸鈣 AS B8 C8 D8 Q.4952 0.4705 0.3978 0.3962 酸鹽 0,3848 0.3838 0.3071 0.2848 氫酯 0.2651 0.2105 0.2021 0.1940 0.1042 0.0929 0.0541 0.0461 0.0375 0.0198 0.0183 0.0147 0.0144 0.0072 0.0052 0.0042 31 (請先W讀背面之注意ί項再填寫本頁) 本紙張尺度逋用中固國家#準(CNS > Α4洗格(2Ι〇Χ297公釐) 410160 A8 B8 C8 D8 0、申讀專利範園 維生素A棕櫊酸酯 0.0041 硫酸廷 0.0037 維生素〇3 0.0036 維生素K 0.0028 維生素Bi2 0.0023 碘化鉀 0.0019 吡哆醇鹽酸殖 0.0018 葉酸 0.0014 核黃素 0.0013 硫胺素鹽酸鹽 0.0012 路酸乙酯單水合物 0.0001 鉬酸鈉 0.0001 亞场酸納無水物 0.00004 全董 100 (請先鬩讀背面之注意事項再填寫本頁) 訂 經濟部4-央搮奉局貝工消费合作社印製 7. 一種對人類青少年供應營養之方法,其包括給予一種 如申請專利範面第1至6項任一項所述之食療組合物, 其中所述之組合物係給予具有疾病_症狀的青少年, 其係選自一群包括發炎性腸疾,難醫治的痢疾,乳糖 不適應症’短暫勝疾症候群,膀胱的織維變性,牛乳 蛋白質勝疾或敏感性’手術前或手術後,後天性免疫 不全症候群,吸收不良症,胃腸炎,f腸瘻管和胰贓 異常者。 32 本紙張尺度連用中《两家揉率(CNS > A4规格(2丨0X297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/309,815 US5719133A (en) | 1994-09-21 | 1994-09-21 | Adolescent dietary composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW410160B true TW410160B (en) | 2000-11-01 |
Family
ID=23199780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084110289A TW410160B (en) | 1994-09-21 | 1995-10-03 | Adolescent dietary composition |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5719133A (zh) |
| EP (1) | EP0705542B1 (zh) |
| AT (1) | ATE161397T1 (zh) |
| CA (1) | CA2158635C (zh) |
| DE (1) | DE69501306T2 (zh) |
| ES (1) | ES2111384T3 (zh) |
| GR (1) | GR3026072T3 (zh) |
| HK (1) | HK1005768A1 (zh) |
| SI (1) | SI0705542T1 (zh) |
| TW (1) | TW410160B (zh) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7455996A (en) | 1995-10-27 | 1997-05-15 | Procter & Gamble Company, The | Color stable iron, zinc and vitamin fortified dry drink mixes |
| GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
| GB9701674D0 (en) * | 1997-01-28 | 1997-03-19 | Novartis Nutrition Ag | Use of organic compounds |
| GB2323030A (en) * | 1997-03-12 | 1998-09-16 | Essential Nutrition Ltd | Dietary supplements for immunocompromised patients |
| WO1998047497A2 (en) * | 1997-04-23 | 1998-10-29 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections |
| US5849335A (en) * | 1997-06-02 | 1998-12-15 | Nestec S.A. | Composition and method for providing glutamine |
| EP1123013A1 (en) * | 1997-06-02 | 2001-08-16 | Société des Produits Nestlé S.A. | Product and method for providing glutamine |
| DE69823739T2 (de) * | 1997-06-05 | 2005-04-28 | Novartis Nutrition Ag | Glycin zur Vorbeugung oder Behandlung von Transplantatabstossungen |
| US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
| US6051270A (en) * | 1997-11-05 | 2000-04-18 | Galagen, Inc. | Liquid amino acid nutritional composition |
| GB9725061D0 (en) * | 1997-11-27 | 1998-01-28 | Tagg Npd Limited | Revitalisation formulation |
| AU2217399A (en) * | 1998-01-07 | 1999-07-26 | Mark E. Jarmel | Promoting mobilization and catabolism of lipids |
| EP1049386A2 (en) * | 1998-01-22 | 2000-11-08 | Abbott Laboratories | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| BR9909234A (pt) | 1998-03-31 | 2000-11-28 | Produites Nestle S A Soc D | Método para fornecimento de glutamina |
| US6288116B1 (en) * | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
| EP1023843B1 (de) * | 1999-01-29 | 2005-06-22 | Sportmedizin Team Vertriebs GmbH | Zusammensetzung zur Leistungsförderung bei sportlicher Tätigkeit, ihre Herstellung und Verwendung als diätetisches Lebensmittel |
| DK1048226T3 (da) * | 1999-04-29 | 2005-10-03 | Nestle Sa | Sammensætning til spædbörnsernæring indeholdende proteiner fra söd valle |
| US6777391B1 (en) | 1999-04-29 | 2004-08-17 | Nestec S.A. | Composition for an infant formula having a low threonine content |
| EP1062879B1 (en) * | 1999-06-26 | 2003-08-27 | B. Braun Melsungen Ag | Aqueous solution for the parenteral nutrition |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| GB0016452D0 (en) * | 2000-07-04 | 2000-08-23 | Kilgowan Limited | Vitamin K and essential fatty acids |
| BR0004436A (pt) * | 2000-08-25 | 2002-04-02 | Univ Minas Gerais | Complemento dietético de aminoácidos, processo para tratamento e prevenção de doenças e processo de administração de um complemento dietético de aminoácidos |
| ATE320831T1 (de) * | 2000-10-06 | 2006-04-15 | Dmg Italia Srl | Immunotrophische preparation zur behandlung von tonsilläre hypertrophie |
| US6552074B2 (en) * | 2000-11-16 | 2003-04-22 | Fukumi Morishige | Arginine/ascorbic acid mixed powder as an oral supplement |
| DE10057290B4 (de) * | 2000-11-17 | 2004-01-08 | Fresenius Kabi Deutschland Gmbh | Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten |
| US6511696B2 (en) * | 2000-12-13 | 2003-01-28 | Novartis Nutrition Ag | Infant formula with free amino acids and nucleotides |
| US20020099037A1 (en) * | 2001-01-19 | 2002-07-25 | Akpharma, Inc. | Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts |
| DE20101225U1 (de) * | 2001-01-24 | 2001-06-13 | Sportmedizin Team Vertriebs Gmbh, Berneck | Präparat für hohe körperliche Beanspruchung |
| EP1372641A4 (en) | 2001-03-05 | 2004-08-25 | Stephen P Ernest | ENTERAL FORMULATION |
| US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| EP1466602A4 (en) * | 2001-12-25 | 2006-03-01 | Ajinomoto Kk | ORGAN FIBROSIS INHIBITORS |
| US6841173B2 (en) * | 2002-03-26 | 2005-01-11 | Peter L. Reynolds | Compositions and methods directed towards sore muscles and joints |
| US6562378B1 (en) | 2002-08-16 | 2003-05-13 | Tsar Health Private Ltd. | Nutritional supplement for adolescents |
| US6565891B1 (en) | 2002-08-23 | 2003-05-20 | Tsar Health Private Ltd. | Nutritional supplement for children |
| US6592908B1 (en) * | 2002-09-23 | 2003-07-15 | Albert Crum | Nutritional or therapeutic compositions |
| AU2003274800A1 (en) * | 2002-10-31 | 2004-05-25 | Lae-Ok Park | Anticancer or antiviral composition |
| CN100448453C (zh) * | 2003-05-22 | 2009-01-07 | 努特里奇亚有限公司 | 治疗或预防慢性创伤的方法及其中所使用的包含甘氨酸和/或亮氨酸的全营养组合物 |
| JP4528925B2 (ja) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | アミノ酸組成物及び補液 |
| ITTO20030789A1 (it) | 2003-10-07 | 2005-04-08 | Professional Dietetics Srl | Composizione a base di amino acidi per il trattamento |
| WO2005110124A1 (en) * | 2004-04-15 | 2005-11-24 | Abbott Laboratories | Composition and methods for nutritional management of patients with hepatic disease |
| US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
| US20070114476A1 (en) * | 2005-11-04 | 2007-05-24 | Williams Christopher P | Low radiocarbon nucleotide and amino acid dietary supplements |
| PL1983849T3 (pl) * | 2006-01-20 | 2013-09-30 | Innova Food Ab | Kompozycja spożywcza zawierająca aminokwasy |
| DE102006018293A1 (de) * | 2006-04-20 | 2007-10-25 | Fresenius Kabi Deutschland Gmbh | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| US8722120B2 (en) * | 2006-08-02 | 2014-05-13 | Mead Johnson Nutrition Company | Amino acid-based nutritional formulations |
| GB0624879D0 (en) * | 2006-12-14 | 2007-01-24 | Shs Int Ltd | Treatment of pervasive development disorders |
| EP2158462A4 (en) | 2007-05-03 | 2010-05-05 | Radiocarb Genetics Inc | FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR |
| JP5527986B2 (ja) * | 2008-02-19 | 2014-06-25 | 株式会社アーネストメディスン | 医薬組成物 |
| KR101325374B1 (ko) * | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
| EP2143340A1 (en) * | 2008-07-07 | 2010-01-13 | Nestec S.A. | A nutritional composition with free amino acids and structured lipids |
| ES2534245T3 (es) | 2008-11-04 | 2015-04-20 | Vymedic, Llc | Formulaciones de suplemento antiviral |
| US20100210600A1 (en) * | 2009-02-19 | 2010-08-19 | Prelief Inc. | Methods and Compositions for Treating Urogenital Disorders |
| WO2011119023A1 (en) * | 2010-03-26 | 2011-09-29 | N.V. Nutricia | Low protein infant formula with increased essential amino acids |
| BR112013033127B1 (pt) | 2011-06-23 | 2020-11-03 | Innovafood Ab | suplemento alimentar, uso do suplemento alimentar, e composição alimentar |
| WO2015085351A1 (en) * | 2013-12-12 | 2015-06-18 | Newsouth Innovations Pty Limited | Pharmaconutrient composition |
| CN107105748A (zh) * | 2014-09-25 | 2017-08-29 | 纽奇瑞迪专业有限公司 | 在青春期前的少年中用于促生长的营养补充剂 |
| US10413528B2 (en) * | 2014-10-20 | 2019-09-17 | John H. Plumb | Methods to inhibit infection during wound healing with topical compositions including amino acids |
| AU2016208455A1 (en) | 2015-01-23 | 2017-06-15 | Société des Produits Nestlé S.A. | Nutritional composition useful in the treatment of IBD patients |
| BR112017026185A2 (pt) * | 2015-06-10 | 2018-08-14 | Ajinomoto Kk | agente e método para melhorar um distúrbio gastrointestinal induzido por exercício. |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| IL296055A (en) | 2017-08-14 | 2022-10-01 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
| WO2019246221A1 (en) * | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
| MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
| WO2020089447A2 (en) | 2018-11-02 | 2020-05-07 | Société des Produits Nestlé S.A. | Powders containing a buffer salt and an amino acid, reconstitution of such a powder into a nutritional product, and methods of using such a nutritional product |
| US11412771B2 (en) * | 2019-04-12 | 2022-08-16 | The Amino Company LLC | Composition to improve athletic performance by supporting muscle protein synthesis and mental focus |
| MX2022004217A (es) * | 2019-10-10 | 2022-07-19 | Axcella Health Inc | Formulas de volumen reducido que incluyen entidades de aminoacidos. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3701666A (en) * | 1968-02-14 | 1972-10-31 | Morton Norwich Products Inc | Process for making amino acid composition |
| US3697287A (en) * | 1969-01-28 | 1972-10-10 | Morton Norwich Products Inc | Amino acid food composition |
| US3773930A (en) * | 1971-03-23 | 1973-11-20 | Johnson & Johnson | Amino acid composition |
| JPS56110617A (en) * | 1980-02-08 | 1981-09-01 | Ajinomoto Co Inc | Nutrient composition for young child |
| SU1228844A1 (ru) * | 1982-11-12 | 1986-05-07 | Московский Городской Научно-Исследовательский Ордена Ленина И Ордена Трудового Красного Знамени Институт Скорой Помощи Им.Н.В.Склифосовского | Смесь дл энтерального зондового питани |
| US4871550A (en) * | 1986-09-05 | 1989-10-03 | Millman Phillip L | Nutrient composition for athletes and method of making and using the same |
| EP0312612B1 (en) * | 1987-05-01 | 1993-03-24 | Otsuka Pharmaceutical Co., Ltd. | Nutritive emulsion |
| US5026721A (en) * | 1989-06-05 | 1991-06-25 | Dudrick Stanley J | Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition |
| DK0421309T4 (da) * | 1989-10-02 | 2003-04-22 | Associated British Foods Plc | Proteinhydrolysater |
| JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
-
1994
- 1994-09-21 US US08/309,815 patent/US5719133A/en not_active Expired - Lifetime
-
1995
- 1995-09-19 ES ES95810580T patent/ES2111384T3/es not_active Expired - Lifetime
- 1995-09-19 AT AT95810580T patent/ATE161397T1/de active
- 1995-09-19 EP EP95810580A patent/EP0705542B1/en not_active Expired - Lifetime
- 1995-09-19 SI SI9530040T patent/SI0705542T1/xx not_active IP Right Cessation
- 1995-09-19 CA CA002158635A patent/CA2158635C/en not_active Expired - Lifetime
- 1995-09-19 DE DE69501306T patent/DE69501306T2/de not_active Expired - Lifetime
- 1995-10-03 TW TW084110289A patent/TW410160B/zh not_active IP Right Cessation
-
1996
- 1996-09-17 US US08/715,298 patent/US5719134A/en not_active Expired - Lifetime
-
1998
- 1998-02-04 GR GR980400240T patent/GR3026072T3/el unknown
- 1998-06-04 HK HK98104872A patent/HK1005768A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0705542B1 (en) | 1997-12-29 |
| DE69501306D1 (de) | 1998-02-05 |
| DE69501306T2 (de) | 1998-06-18 |
| EP0705542A1 (en) | 1996-04-10 |
| SI0705542T1 (en) | 1998-04-30 |
| ATE161397T1 (de) | 1998-01-15 |
| CA2158635C (en) | 1998-05-12 |
| ES2111384T3 (es) | 1998-03-01 |
| CA2158635A1 (en) | 1996-03-22 |
| HK1005768A1 (zh) | 1999-01-22 |
| GR3026072T3 (en) | 1998-05-29 |
| US5719133A (en) | 1998-02-17 |
| US5719134A (en) | 1998-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW410160B (en) | Adolescent dietary composition | |
| US6241996B1 (en) | Liquid soy nutritional products | |
| CN101061860B (zh) | 富含亮氨酸的营养组合物 | |
| CA2133783C (en) | Enteral nutritional composition | |
| RU2243698C2 (ru) | Композиция для детского питания (варианты) и способ получения белкового гидролизата | |
| HK1005768B (zh) | 青少年限制饮食的成分 | |
| ES2677868T3 (es) | Composición nutricional frente a los efectos secundarios de la quimioterapia o de la radioterapia | |
| JP5315996B2 (ja) | 総合経腸栄養組成物 | |
| TW301600B (zh) | ||
| US20090075862A1 (en) | Method for providing glutamine | |
| KR20080080988A (ko) | 장쇄 다중불포화 지방산을 함유하는 영양 보충물 | |
| CN105054001A (zh) | 包含辛烯基琥珀酸酐-改性木薯淀粉的营养制剂 | |
| CA2347172A1 (en) | Protein material for slow digestion and its use | |
| JPH1118725A (ja) | 糖尿病患者用栄養組成物 | |
| BR112016030759B1 (pt) | Composições nutricionais entéricas e uso da composição | |
| RU2385647C2 (ru) | Питание для пациентов, страдающих ожирением | |
| JP2002538797A (ja) | 未成熟哺乳動物の特定の胃腸成熟用に意図した栄養組成物 | |
| US5849335A (en) | Composition and method for providing glutamine | |
| SG195569A1 (en) | Nutritional composition with anti-regurgitation properties | |
| JP3907098B2 (ja) | 栄養飲料またはゼリー | |
| CN110547476A (zh) | 快速补充能量的蛋白组合物 | |
| US20030091613A1 (en) | Gelled nutritional composition and process | |
| JP2750467B2 (ja) | ペプチド混合物及び経腸栄養組成物 | |
| BR112019008749B1 (pt) | Pufa, vitamina e, vitamina d e os aminoácidos ligados às proteínas glicina, arginina e triptofano, seu uso na fabricação de uma composição nutricional para tratar câncer, composição nutricional e unidade de dosagem | |
| RU2311039C2 (ru) | Продукт энтерального питания "нутриэн фтизио" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |